• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase

    5/6/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026.

    InMode Logo (PRNewsfoto/InMode)

    First Quarter 2026 Highlights:



    ●  Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.



    ●  Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.

    ●  GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.

    ●  Total cash position of $537.2 million as of March 31, 2026, including cash and cash equivalents, marketable securities and short-term bank deposits.

    ●  As of March 31, 2026, we completed the repurchase of 2.55 million ordinary shares pursuant to our share repurchase program, returning $34.8 million of capital to shareholders ($3.6 million of which was paid during the second quarter of 2026).

    ●  Announced CFO transition; Yair Malca steps down and will support an orderly transition as a consultant.

    ●  Board transition: Dr. Michael Anghel resigns; Dr. Hadar Ron appointed Interim Chair of the Board.

     

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q1 2026

    Q1 2025

    Revenues

    $82,017

    $77,874

    Gross Margins

    75 %

    78 %

    Operating Margins

    12 %

    20 %

    Net Income

    $11,562

    $18,201

    Earnings per Diluted Share

    $0.18

    $0.26

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q1 2026

    Q1 2025

    Gross Margins

    75 %

    79 %

    Operating Margins

    17 %

    23 %

    Net Income

    $15,872

    $21,395

    Earnings per Diluted Share

    $0.25

    $0.31

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A

    reconciliation between U.S. GAAP and non-GAAP Statement of Income
    is provided following the financial statements included in this release.

    Non-GAAP results exclude share-based compensation, expenses related to independent transaction committee review (representing non-

    recurring cost) and related income tax adjustments where applicable.

     

    Management Comments

    "While the macroeconomic environment remains challenging, our total revenue this quarter reached our expectations, however our profitability was lower than expected," said Moshe Mizrahy, Chief Executive Officer of InMode.  "We are continuing to re-shape our organization in North America and in Europe by enhancing our sales and management teams. While the demand in the aesthetics market may be deferred, it will not be diminished, and we believe we are well positioned for its return."

    First Quarter 2026 Financial Results

    Total GAAP revenues for the first quarter of 2026 were $82.0 million, an increase of 5% compared to $77.9 million in the first quarter of 2025. 

    Yair Malca, Chief Financial Officer of InMode added, "We are encouraged to report that Q1 revenue increased 5% year over year, with the U.S. contributing meaningfully to this growth. These results reflect our ability to execute consistently, even in a softer market environment and expand outside of the U.S."

    GAAP gross margin for the first quarter of 2026 was 75%, compared to 78% for the first quarter of 2025.

    *Non-GAAP gross margin for the first quarter of 2026 was 75%, compared to 79% for the first quarter of 2025.

    GAAP operating margin for the first quarter of 2026 was 12%, compared to 20% in the first quarter of 2025.

    *Non-GAAP operating margin for the first quarter of 2026 was 17%, compared to 23% for the first quarter of 2025. These decreases were primarily attributable to the increase in cost of goods, the new structure of the North America sales team implemented towards end of 2025 and subsidiary establishments in the latter part of 2025.

    InMode reported GAAP net income of $11.6 million, or $0.18 per diluted share, in the first quarter of 2026, compared to $18.2 million, or $0.26 per diluted share, in the first quarter of 2025. On a *non-GAAP basis, InMode reported net income of $15.9 million, or $0.25 per diluted share, in the first quarter of 2026, compared to $21.4 million, or $0.31 per diluted share, in the first quarter of 2025.

    As of March 31, 2026, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $537.2 million.

    "In a quarter marked by ongoing macroeconomic uncertainty, we remained focused on what we can control: driving profitability, generating cash, and operating the business as usual. We also returned meaningful capital to shareholders, repurchasing $127.4 million of shares during 2025 and $52.7 million year to date under our new 2026 repurchase program, representing 3.86 million shares. With our strong financial position and continued flexibility, we remain well positioned to pursue a full range of capital allocation opportunities," concluded Malca.

    Departure of Chairman; Resignation of Chief Financial Officer

    The Company announced today that Dr. Michael Anghel has resigned from the Company's Board of Directors, effective May 5, 2026. His decision was not related to any disagreements with the Company's management, Board, or operations. The Company thanks Dr. Anghel for his service and wishes him continued success.

    Dr. Hadar Ron has been appointed Interim Chair of the Board, effective immediately.

    Separately, Yair Malca has stepped down from his role as Chief Financial Officer, effective May 5, 2026. The Company appreciates his contributions and thanks him for his service.

    To support a smooth transition, Mr. Malca will remain engaged with the Company in a consulting capacity for at least six months.

    2026 Financial Outlook

    Management provided an outlook for the full fiscal year ending December 31, 2026. Based on current estimates, management expects:

    • Revenues between $365 million and $375 million
    • *Non-GAAP gross margin between 74% and 76%
    • *Non-GAAP income from operations to be between $73 million and $78 million
    • *Non-GAAP earnings per diluted share between $1.33 and $1.38

    This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-Looking Statements" for additional information.

    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation, expenses related to independent transaction committee review (representing non-recurring cost) and related income tax adjustments where applicable.

    However, these estimates are based on management's current estimates, which may be updated. 

    The Current Situation in Israel

    Regarding the current situation in Israel, on October 9, 2025, a new cease-fire agreement between Hamas and Israel began, and the hostilities have formally paused after two years of conflicts.

    Moreover, On February 28, 2026, the United States and Israel launched coordinated joint military strikes against Iran, targeting military, governmental, and nuclear-related sites. Iran subsequently responded with missile and drone attacks against targets in the region and sought to restrict commercial shipping traffic through the Strait of Hormuz. On April 7, 2026, a two-week ceasefire established and was extended on April 21, 2026, by the U.S government, amid ongoing negotiations, while a U.S. naval blockade of Iran continued.

    The scope and severity of ongoing conflicts in Gaza, Northern Israel, Lebanon, Iran, and the broader region are unpredictable and could escalate any time. To date, our operations have not been materially affected. We continue to monitor political and military developments closely and examine the consequences for our operations and assets. 

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin, non-GAAP gross margin and non-GAAP income from operations. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release. Reconciliations of non-GAAP gross margin, non-GAAP income, and non-GAAP earnings for management's projections of such non-GAAP financials for the 2026 fiscal year are not available without unreasonable effort due to the variability, complexity and limited visibility of certain reconciling items. These reconciling items could have a significant and unpredictable impact on our future GAAP results.

    Conference Call Information

    Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer and Mr. Yair Malca, Chief Financial Officer, will host a conference call today, May 6, 2026, at 8:30 a.m. Eastern Time to discuss the first quarter 2026 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10207930/103b6ad5664.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S./Canada Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll-Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=7s0HUsXw

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from May 6, 2026, at 12 p.m. Eastern Time to May 20, 2026, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S. /Canada TOLL-FREE: 1-855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 8622780

    To access the replay using an international dial-in number, please select the link below:

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements 

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: Yair.Malca@inmodemd.com

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: ir@inmodemd.com

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    Three months ended

    March 31,



    2026



    2025

    REVENUES

    82,017



    77,874

    COST OF REVENUES

    20,465



    16,963

    GROSS PROFIT

    61,552



    60,911

    OPERATING EXPENSES:







    Research and development

    3,542



    2,895

    Sales and marketing

    42,932



    39,727

    General and administrative

    5,022



    2,671

    TOTAL OPERATING EXPENSES

    51,496



    45,293

    OPERATING INCOME

    10,056



    15,618

    Finance income, net

    4,296



    6,859

    INCOME BEFORE INCOME TAXES

    14,352



    22,477

    INCOME TAXES

    2,790



    4,276

    NET INCOME

    11,562



    18,201









    EARNINGS PER SHARE:







    Basic

    0.18



    0.26

    Diluted

    0.18



    0.26

    WEIGHTED AVERAGE NUMBER OF SHARES

    OUTSTANDING USED IN COMPUTATION OF EARNINGS PER

    SHARE (in thousands)







    Basic

    63,401



    68,760

    Diluted

    63,942



    69,435

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)



    March 31,

    2026

    December 31,

    2025

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    394,295

    302,543

    Marketable securities

    57,032

    83,632

    Short-term bank deposits

    85,832

    169,159

    Accounts receivable, net of allowance for credit losses

    40,703

    43,504

    Prepaid expenses and other receivables

    31,509

    25,733

    Inventories

    71,408

    74,050

             TOTAL CURRENT ASSETS

    680,779

    698,621

        NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for credit losses

    5,210

    3,005

    Deferred income tax assets

    52,922

    53,230

    Operating lease right-of-use assets

    8,631

    8,274

    Property and equipment, net

    2,595

    2,599

    Other investments

    700

    700

    TOTAL NON-CURRENT ASSETS

    70,058

    67,808

    TOTAL ASSETS

    750,837

    766,429

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payables

    16,853

    17,912

    Contract liabilities

    16,369

    12,093

    Other liabilities

    44,131

    40,739

    TOTAL CURRENT LIABILITIES

    77,353

    70,744

        NON-CURRENT LIABILITIES:





    Contract liabilities

    2,745

    3,043

    Other liabilities

    4,657

    4,436

    Operating lease liabilities

    4,829

    5,008

    TOTAL NON-CURRENT LIABILITIES

    12,231

    12,487

    TOTAL LIABILITIES

    89,584

    83,231







    TOTAL SHAREHOLDERS' EQUITY

    661,253

    683,198

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    750,837

    766,429

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)











    Three months ended

    March 31,





    2026



    2025

    CASH FLOWS FROM OPERATING ACTIVITIES:













    Net income





    11,562





    18,201

    Adjustments required to reconcile net income to net cash provided by operating activities:













    Depreciation and amortization





    175





    174

    Share-based compensation expenses





    2,699





    2,518

    Change in allowance for credit losses of trade receivable





    525





    (94)

    Gains on marketable securities, net





    –





    (2)

    Finance expenses (income), net





    719





    (1,574)

    Deferred income taxes, net





    327





    896

    Changes in operating assets and liabilities:













    Decrease in accounts receivable (current and non-current)





    72





    4,544

    Increase in other receivables





    (5,866)





    (3,532)

    Decrease (increase) in inventories





    2,642





    (4,233)

    Increase (decrease) in accounts payable





    (1,059)





    1,270

    Decrease in other liabilities (current and non-current)





    (388)





    (3,287)

    Increase (decrease) in contract liabilities (current and non-current)





    3,978





    (837)

    Net cash provided by operating activities





    15,386





    14,044

    CASH FLOWS FROM INVESTING ACTIVITIES:













    Investment in short-term deposits





    (84,912)





    –

    Proceeds from short-term deposits





    167,658





    31,297

    Purchase of fixed assets





    (172)





    (85)

    Purchase of marketable securities





    (9,727)





    (20,877)

    Proceeds from sale of marketable securities





    –





    3,003

    Proceeds from maturity of marketable securities





    36,256





    62,147

    Net cash provided by investing activities





    109,103





    75,485

    CASH FLOWS FROM FINANCING ACTIVITIES:













    Tax withholding related to vesting of restricted share units





    (1,802)





    -

    Repurchase of ordinary shares





    (31,241)





    (99,960)

    Exercise of options





    617





    494

    Net cash used in financing activities





    (32,426)





    (99,466)

    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH

        EQUIVALENTS





     

    (311)





     

    556

    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS





    91,752





    (9,381)















    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD





    302,543





    155,329

    CASH AND CASH EQUIVALENTS AT END OF PERIOD





    394,295





    145,948

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)







    Three months ended March 31,

    2026

    2025

    Revenues by Category:























    Capital Equipment revenues - United States

    33,669

    41 %

    29,542

    38 %



    Capital Equipment revenues - International

    26,985

    33 %

    28,133

    36 %



    Total Capital Equipment revenues

    60,654

    74 %

    57,675

    74 %



    Consumables and service revenues

    21,363

    26 %

    20,199

    26 %



    Total Revenue

    82,017

    100 %

    77,874

    100 %



     



    Three months ended March 31,

    2026

    2025



    %

    %



    United

    States

    International

    Total

    United

    States

    International

    Total

    Revenues by Technology:













    Minimal-Invasive

    75

    80

    77

    93

    79

    87

    Hands-Free

    1

    1

    1

    3

    2

    3

    Non-Invasive

    24

    19

    22

    4

    19

    10



    100

    100

    100

    100

    100

    100

     

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)

















    Three months ended March 31, 2026



    Three months ended March 31, 2025







    GAAP



    Stock Based

    Compensation



    Expenses

    Related to

    Independent

    Transaction

    Committee Review



    Non-GAAP



    GAAP



    Stock Based

    Compensation



    Non-GAAP

    REVENUES



    82,017



    –



    –



    82,017



    77,874



    –



    77,874

    COST OF REVENUES



    20,465



    (314)



    –



    20,151



    16,963



    (310)



    16,653

    GROSS PROFIT



    61,552



    314



    –



    61,866



    60,911



    310



    61,221

    OPERATING EXPENSES:





























    Research and development



    3,542



    (268)



    –



    3,274



    2,895



    (222)



    2,673

    Sales and marketing



    42,932



    (1,861)



    –



    41,071



    39,727



    (1,763)



    37,964

    General and administrative



    5,022



    (256)



    (1,262)



    3,504



    2,671



    (223)



    2,448

    TOTAL OPERATING EXPENSES



    51,496



    (2,385)



    (1,262)



    47,849



    45,293



    (2,208)



    43,085

    OPERATING INCOME



    10,056



    2,699



    1,262



    14,017



    15,618



    2,518



    18,136

    Finance income, net



    4,296



    –



    –



    4,296



    6,859



    –



    6,859

    INCOME BEFORE INCOME TAXES



    14,352



    2,699



    1,262



    18,313



    22,477



    2,518



    24,995

    INCOME TAXES



    2,790



    (349)



    –



    2,441



    4,276



    (676)



    3,600

    NET INCOME



    11,562



    3,048



    1,262



    15,872



    18,201



    3,194



    21,395































    EARNINGS PER SHARE





























    Basic



    0.18











    0.25



    0.26







    0.31

    Diluted



    0.18











    0.25



    0.26







    0.31

    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF NET INCOME PER

    SHARE (in Thousands)





























    Basic



    63,401











    63,401



    68,760







    68,760

    Diluted



    63,942











    64,494



    69,435







    69,611

     

    Logo - https://mma.prnewswire.com/media/1064477/5954733/InMode_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-reports-first-quarter-2026-financial-results-quarterly-gaap-revenue-of-82-million-represents-5-year-over-year-increase-302763182.html

    SOURCE InMode LTD.

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

    Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea

    5/27/26 9:00:00 AM ET
    $ESTA
    $INMD
    $PCRX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

    YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun

    5/20/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at Upcoming Investor Conferences and Events

    YOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events:  Barclays Virtual West Coast Bus TripPresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: Virtual investor bus tourWhen: Wednesday, May 20Jefferies Global Healthcare ConferencePresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst and one-on-one meetingsWhen: Wednesday, June 3, fireside chat at 12:45 p

    5/13/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    5/20/26 7:04:11 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    5/6/26 7:00:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Moshe Itzkovich claimed ownership of 7,503 units of Ordinary Shares (SEC Form 3)

    3 - InMode Ltd. (0001742692) (Issuer)

    5/26/26 4:30:34 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Nass Shlomo claimed no ownership of stock in the company (SEC Form 3)

    3 - InMode Ltd. (0001742692) (Issuer)

    5/26/26 4:30:39 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

    Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea

    5/27/26 9:00:00 AM ET
    $ESTA
    $INMD
    $PCRX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer

    YOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun

    5/20/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase

    YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026. First Quarter 2026 Highlights:●  Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.●  Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.●  GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.●  Total cash po

    5/6/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care